Literature DB >> 6111325

[On the pharmacology of the alpha-receptor blocker BE 2254 (HEAT) (author's transl)].

N Heinz, E Hofferber.   

Abstract

The alpha-adrenolytic activity of BE 2254 was investigated in in vitro as well as in vivo assays. On the isolated rat anococcygeus muscle, 2-[beta-(4-hydroxyphenyl)-ethyl-amino-methyl]tetralone(1) (BE 2254) shows a high affinity for postsynaptic alpha-adrenoceptors (pA2 = 8.9), in contrast to its much weaker potency (pA2 = 6.7) in inhibiting clonidine on the electrically driven rat vas deferens, thus suggesting a relative preference for postsynaptic alpha-adrenoceptors. BE 2254 effects on other catecholamine receptors are either negligible or not detectable. The hypotensive action of BE 2254 is shown to be solely due to alpha-blockade. All alpha-adrenolytic actions studied were of competitive nature.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6111325

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  4 in total

1.  Effects of alpha-adrenoceptor antagonists on the release of serotonin and noradrenaline from rat brain cortex slices. Influence of noradrenaline uptake inhibition and determination of pA2 values.

Authors:  E Schlicker; M Göthert; F Köstermann; R Clausing
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-06       Impact factor: 3.000

2.  [125I]-HEAT, a selective, high-affinity, high specific activity ligand for alpha 1-adrenoceptors.

Authors:  H Glossmann; F Lübbecke; P Bellemann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-12       Impact factor: 3.000

3.  A study of alpha 1-adrenoceptors in rat renal cortex: comparison of [3H]-prazosin binding with the alpha 1-adrenoceptor modulating gluconeogenesis under physiological conditions.

Authors:  G A McPherson; R J Summers
Journal:  Br J Pharmacol       Date:  1982-09       Impact factor: 8.739

4.  Studies on YM-12617: a selective and potent antagonist of postsynaptic alpha 1-adrenoceptors.

Authors:  K Honda; T Takenaka; A Miyata-Osawa; M Terai; K Shiono
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-01       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.